Automating Hope: A New Era in Personalized Cancer Vaccine Manufacturing

RIO RANCHO, NM – August 19, 2026 – The promise of personalized medicine, particularly in the fight against cancer, has long been a beacon of hope. The concept is elegant: create a unique therapy for each patient, tailored to the specific molecular fingerprint of their disease. Yet, this vision has consistently collided with a formidable, unglamorous obstacle: manufacturing. How do you reliably, consistently, and affordably produce a unique drug for a single person, and then do it again for the next, and the next?

A recent announcement from New Mexico-based NTx Bio suggests a critical piece of this puzzle may be falling into place. The company’s automated biomanufacturing platform, NTxscribe® CORE, is now being used by researchers at Baylor College of Medicine to produce a personalized cancer vaccine for a Phase 1 clinical trial. The trial, sponsored by Diakonos Oncology, targets refractory melanoma, a deadly form of skin cancer that has stopped responding to standard treatments. This collaboration marks one of the first publicly disclosed clinical uses of NTx Bio's technology, moving it from a theoretical advantage to a tangible component in the delivery of a potentially life-saving therapy.

Cracking the Code of Personalized Manufacturing

The central challenge in cell and gene therapy is variability. When your starting material is a patient’s own tissue, each manufacturing run is, by definition, a custom job. Traditional biomanufacturing, built for mass production of a single product, is ill-suited for this “batch of one” paradigm. The process is often highly manual, demanding skilled labor and multiple, disparate pieces of equipment, which introduces opportunities for error and inconsistency.

"Manufacturing consistency is one of the biggest hidden challenges in personalized cell and gene therapies," said Joan Haab, Ph.D., CEO of NTx Bio. This is the problem NTx Bio aims to solve. Its platform automates a crucial, complex step: the generation of messenger RNA (mRNA) from a patient’s tumor.

At Baylor, researchers use NTxscribe to amplify the tumor mRNA from very small surgical biopsies. This mRNA contains the genetic instructions for all the proteins—including the aberrant ones that mark cells as cancerous—present in that patient's tumor. The resulting mRNA is then used to “educate” the patient’s own immune cells. Critically, the platform faithfully preserves the full-length range of the tumor’s genetic transcripts, ensuring the vaccine carries a complete and accurate representation of the tumor antigens the immune system needs to target.

"Working with patient-derived material means we don't get the luxury of a standardized starting point," explained William Decker, Ph.D., Professor of Pathology & Immunology at Baylor College of Medicine and the inventor of the vaccine technology. "Automating the mRNA generation step with NTxscribe is solving the most challenging, time intensive, and variable step in the manufacturing process so we can focus our attention on delivering a high-quality product to more patients.”

This sentiment is echoed by his colleague, Vanaja Konduri, Ph.D., an Assistant Professor of Immunology who invented the mRNA amplification procedure. “NTxscribe has really improved reproducibility while virtually eliminating batch to batch variability,” she agreed. By replacing manual steps with a closed, continuous-flow system, the platform provides the consistency necessary for clinical-grade production, patient after patient.

A New Lifeline for Refractory Melanoma

The immediate impact of this manufacturing breakthrough is being felt by patients with few remaining options. The Diakonos trial, known as DOC-RM (NCT07288112), is enrolling patients with unresectable or metastatic melanoma who have already failed treatment with immune checkpoint inhibitors (ICIs), the current standard of care. This is a significant unmet need; up to 55% of patients show primary resistance to ICIs, and many who initially respond eventually relapse.

The vaccine at the heart of the trial, DOC1021 (dubodencel), is a first-in-class dendritic cell therapy. Dendritic cells are the sentinels of the immune system, responsible for presenting foreign or dangerous antigens to T-cells to initiate an attack. The Diakonos approach involves taking a patient's own dendritic cells and “double-loading” them with two sets of instructions: a lysate made from the patient’s own tumor and the amplified tumor-derived mRNA produced by the NTxscribe system. This proprietary method is designed to mimic the powerful immune activation that occurs during a viral infection, generating a broad, potent, and highly personalized anti-tumor response.

While data from the melanoma trial is forthcoming, DOC1021 has already shown a strong safety profile and promising signs of efficacy in trials for other aggressive cancers, including glioblastoma. In that setting, the therapy demonstrated a substantial survival benefit compared to standard of care, with no dose-limiting toxicities observed across studies. For melanoma patients who have exhausted other therapies, this novel approach offers a new and potentially more effective strategy.

The Collaborative Engine of Innovation

This story is a powerful illustration of the modern ecosystem required to bring advanced therapies to market. It represents a synergy between three distinct but complementary entities: academic research, clinical-stage biotechnology, and enabling technology.

Baylor College of Medicine serves as the engine of discovery, where the fundamental science behind the dendritic cell vaccine was developed over years of research. Diakonos Oncology, a clinical-stage company founded on Baylor's research, acts as the translational vehicle. It navigates the complex clinical and regulatory pathways, secures funding—including a recent $20 million round with participation from a Baylor-affiliated fund—and designs the trials to prove the therapy's worth. The FDA has recognized the platform's potential by granting it Fast Track designation not only for melanoma but also for pancreatic cancer and glioblastoma.

Into this partnership steps NTx Bio, providing the critical enabling technology. It is the “pick-and-shovel” play in this gold rush for personalized medicine, offering a solution that addresses a fundamental operational bottleneck. Without a scalable and reproducible manufacturing process, even the most brilliant scientific discovery remains confined to the lab. This tripartite collaboration provides a potential blueprint for how to successfully translate complex, individualized therapies from bench to bedside.

As the field of personalized oncology grows, with competitors like Moderna and Merck advancing their own mRNA-based cancer vaccines, the underlying manufacturing technology will become an increasingly important point of differentiation. The ability to automate, ensure quality, and scale production is not just an operational advantage; it is a strategic imperative. "Seeing NTxscribe support a program like DOC1021, from a patient's own tumor DNA all the way to a dosed patient, is exactly the kind of real-world validation we set out to deliver when we built this platform," Haab stated. By providing a robust, scalable manufacturing solution, such platforms are not just supporting clinical trials; they are laying the groundwork for the future delivery of personalized medicine.